查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1137021

结合型疫苗市场:各产品类型，疾病各适应症，各病原体类型，各患者类型，各地区- 规模，占有率，展望，机会分析，2022年～2030年

Conjugate Vaccine Market, by Product Type, by Disease Indication, by Pathogen Type, by Patient Type, and by region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 186 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场动态

预计在预测期内，越来越多的肺炎患者将推动全球结合疫苗市场的增长。

本调查的主要特征

  • 本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球结合型疫苗市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
  • 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
  • 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
  • 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球结合型疫苗市场的主要参与者之企业简介。
  • 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 全球结合型疫苗市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以透过全球结合型疫苗市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

目录

第1章 调查目的与前提条件

  • 调查目的
  • 前提条件
  • 简称的说明

第2章 市场展望

  • 报告内容
  • 市场定义和范围
  • 摘要整理
    • 市场概述:各产品类型
    • 市场概述:疾病各适应症
    • 市场概述:各病原体类型
    • 市场概述:各患者类型
    • 市场概述:各地区
  • 连贯机遇地图(COM)

第3章 市场动态，法规，及趋势的分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 市场趋势
  • 主要的发展情形
  • 产品平台分析
  • 投资和政府的配合措施
  • GAVI及PATH计划详细内容
  • 合併和收购
  • 法规方案
  • PORTER'S五力
  • PEST分析

第4章 全球结合型疫苗市场-冠状病毒(COVID-19)疫情的影响

  • 整体影响
  • COVID-19市场的影响

第5章 结合型疫苗的全球市场:各产品类型，2017年～2030年

  • 一价结合型疫苗
  • 多效价结合型疫苗

第6章 结合型疫苗的全球市场:疾病各适应症，2017年～2030年

  • 肺炎球菌
  • 流感
  • 脑膜炎
  • 伤寒症

第7章 结合型疫苗的全球市场，各病原体类型，2017年～2030年

  • 细菌性
  • 病毒性

第8章 结合型疫苗的全球市场:各患者类型，2017年～2030年

  • 儿童用
  • 成人用

第9章 结合型疫苗的全球市场:各地区，2017年～2030年

  • 北美
  • 美国
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他的南美地区
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 中东地区
  • GCC
  • 以色列
  • 其他的中东地区
  • 非洲
  • 北非
  • 中非
  • 南非

第10章 竞争情形

  • 热图分析
  • 企业简介
    • Sanofi S.A
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc.
    • Bharat Biotech
    • Serum institute of India Pvt. Ltd
    • Biological E. Limited.
    • Bio-Med
    • Biological E Limited
    • CSL Limited
    • Novartis AG
    • Vaxcyte
    • GSBPL
    • Taj Pharmaceuticals Limited.
    • Bavarian Nordic

第11章 章节

  • 参考文献
  • 调查手法的介绍
  • 关于出版社
简介目录
Product Code: CMI2697

Conjugate vaccine is a combination of a weak antigen with a strong antigen so as to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, on January 24, 2022 according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. Whereas in 2021, US FDA (Food and Drug Administration) licensed PCV15 and PCV20 for use in adults 18 years or older. Clinical trial data showed that PCV15 and PCV20 caused the body's immune system to create antibodies, which helped fight the pneumococcal bacteria, similar to PCV13.

Market Dynamics

Increasing prevalence of pneumonia cases are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in August 2021, National Center for Biotechnology Information, published a report on Community-Acquired Pneumonia, which reported that the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the U.S., the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases, whereas the mortality rate is as high as 23% for patients admitted to the intensive care unit.

Increasing initiatives taken by the governments of countries to launch new vaccines are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in October 2021, Union Health Minister (India), Dr. Mansukh Mandaviya, launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) as a part of Azadi ka Amrit Mahotsav. Whereas, on the other hand communication and awareness packages on PVC were also made available in India.

Key features of the study:

  • This report provides an in-depth analysis of the global conjugate vaccine market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2030), considering 2021, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global conjugate vaccine market based on following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include, Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, Bio-Med, Bavarian Nordic, CSL Limited, Novartis AG, Vaxcyte, GSBPL, Taj Pharmaceuticals Limited, and Bavarian Nordic
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global conjugate vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global conjugate vaccine market

Detailed Segmentation:

  • Global Conjugate Vaccine Market, By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
  • Global Conjugate Vaccine Market, By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
  • Global Conjugate Vaccine Market, By Pathogen Type:
    • Bacterial
    • Viral
  • Global Conjugate Vaccine Market, By Patients Type:
    • Pediatric
    • Adults
  • Global Conjugate Vaccine Market, By Region:
    • North America
      • By country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Sanofi S.A*
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Bharat Biotech.
    • Serum institute of India Pvt. Ltd.
    • Biological E. Limited
    • Bio-Med
    • Biological E Limited
    • CSL Limited
    • Novartis AG
    • Vaxcyte
    • GSBPL
    • Taj Pharmaceuticals Limited.
    • Bavarian Nordic

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product Type
    • Market Snapshot, By Disease Indication
    • Market Snapshot, By Pathogen Type
    • Market Snapshot, By Patient Types
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Product Pipeline Analysis
  • Investments and Government Initiatives
  • GAVI and PATH Program Details
  • Merger and Acquisition
  • Regulatory Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Global Conjugate Vaccine Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • COVID-19 Impact on the market

5. Global Conjugate Vaccine Market, By Product Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Monovalent Conjugate Vaccine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Multivalent Conjugate Vaccine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Conjugate Vaccine Market, By Disease Indication, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Pneumococcal
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Influenza
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Meningococcal
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Typhoid
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Conjugate Vaccine Market, By Pathogen Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Bacterial
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Viral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Conjugate Vaccine Market, By Patient Type,2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017- 2030
    • Segment Trends
  • Paediatric
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Adult
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Conjugate Vaccine Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Pathogen Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Heat Map Analysis
  • Company Profile
    • Sanofi S.A
  • Company Highlights
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Market Strategies
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc.
    • Bharat Biotech
    • Serum institute of India Pvt. Ltd
    • Biological E. Limited.
    • Bio-Med
    • Biological E Limited
    • CSL Limited
    • Novartis AG
    • Vaxcyte
    • GSBPL
    • Taj Pharmaceuticals Limited.
    • Bavarian Nordic
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About Us